601316 Provided are polymorphs and solvates of the hydrochloride salt of 4- [2-[[5- methyl-1-(2-naphthalenyl)-1 H-pyrazol-3-yl]oxy]ethyl]morpholine (P027), processes for their preparation, and pharmaceutical compositions comprising them. XRD data for the polymorphs and solvates is as follows: a polymorphic phase I form having characteristics peaks at a reflection angle [2theta in degrees] of about 5.9, 8.1, 11.3, 11.7, 14.2, 15.1, 15.8, 16.3, 16.8, 17.8, 18.1, 18.6, 19.8, 20.9, 21.9, 22.8, 23.0, 23.2, 23.6, 23.9, 24.3, 25.0, 25.1, 28.0, 28.3, 28.6, 29.0, 29.2, 30.7, and 30.9 a polymorphic phase II form having characteristics peaks at a reflection angle [2theta in degrees] of about 5.776, 11.629, 14.558, 15.737, 15.891, 16.420, 16.740, 17.441, 17.635, 18.056, 18.219, 19.232, 19.712, 20.140, 20.685, 21.135, 21.889, 22.108, 22.478, 22.763, 23.219, 23.454, 23.782, 24.689, 25.065, and 25.671 a polymorphic phase III form having characteristics peaks at a reflection angle [2theta in degrees] of about 5.437, 5.714, 10.918, 11.546, 12.704, 13.344, 13.984, 14.505, 15.606, 15.824, 16.164, 16.646, 17.333, 17.837, 18.719, 18.878, 19.236, 19.533, 20.142, 20.689, 21.337, 22.008, 22.929, 23.596, 24.748, 25.064, 25.207, 25.737, and 26.148 a polymorphic phase IV form having characteristics peaks at a reflection angle [2theta in degrees] of about 5.805, 11.685, 15.559, 15.804, 16.397, 16.879, 17.357, 17.465, 17.621, 19.112, 19.435, 19.923, 21.224, 21.987, 22.167, 22.412, 2.852, 23.059, 23.359, 23.855, 24.092, 25.722, 26.054, 26.649, and 27.780 a dioxane solvate having characteristics peaks at a reflection angle [2theta in degrees] of about 4.734, 9.317, 11.390, 13.614, 14.290, 14.815, 16.211, 16.432, 16.782, 17.741, 18.056, 18.329, 18.724, 19.070, 19.494, 20.436, 20.762, 21.587, 22.000, 22.935, 23.084, 23.551, 23.891, 24.721, and 25.078 and a chloroform solvate having characteristics peaks at a reflection angle [2theta in degrees] of about 11.370, 13.396, 14.048, 15.010, 15.303, 16.11
